Data source details

*
None
None

GSK and Online Communities Create Unique Alliance to Stimulate Open Source Drug Discovery for Malaria

Francisco-Javier Gamo, Laura M. Sanz, Jaume Vidal, Cristina de Cozar, Emilio Alvarez, Jose-Luis Lavandera, Dana E. Vanderwall, Darren V. S. Green, Vinod Kumar, Samiul Hasan, James R. Brown, Catherine E. Peishoff, Lon R. Cardon and Jose F. Garcia-Bustos. Thousands of chemical starting points for antimalarial lead identification. Nature 465(7296) 305-310 (2010) Link to Publication
 -- GSK becomes first company to freely share chemical structures on 13,500 molecules from its compound library  -- Alliances formed with leading scientific research communities from private industry and public-domain data providers

BURLINGAME, Calif., May 20 /PRNewswire/ -- GlaxoSmithKline (GSK) had teamed up with leading public-domain data providers European Bioinformatics Institute (EMBL-EBI), the U.S. National Library of Medicine (NLM) and the U.S.-based informatics service provider Collaborative Drug Discovery (CDD) to make freely available key scientific information on more than 13,500 compounds that could ultimately lead to new treatments for malaria.

The release of this data marks the first time that a pharmaceutical company has made available the structures of so many compounds and is made possible through the collaboration of the web hosts and their specialist research tools, which will be available at no cost to researchers. The information, which is hosted on websites regularly used by researchers, includes high quality scientific data about the molecules from GSK's own compound library which have demonstrated potency against the most deadly malaria parasite, P. falciparum.



GlaxoSmithKline  

 

 

 


 

 

 

 

United Kingdom 

Biological Properties



 

 

 

Yes

No

No


Feedback Form